[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi
Hitoshi
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016227:Benzoquinones; D002227:Carbazoles / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D005663:Furans; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D047029:Lactams, Macrocyclic; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D011809:Quinones / Q000627:therapeutic use; D017828:Rifabutin / Q000031:analogs & derivatives; D019311:Staurosporine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000077210:Sunitinib; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology / Q000502:physiology
D000911:Antibodies, Monoclonal; D016227:Benzoquinones; D002227:Carbazoles; D004791:Enzyme Inhibitors; D005663:Furans; D007211:Indoles; D047029:Lactams, Macrocyclic; D010879:Piperazines; D011758:Pyrroles; D011799:Quinazolines; D011809:Quinones; D017828:Rifabutin; C020754:herbimycin; C119379:lestaurtinib; C464670:tandutinib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D019311:Staurosporine; C059539:midostaurin; D000077210:Sunitinib